

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE	:	ORDER OF THE
CONTROLLED SUBSTANCES BOARD	:	CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On December 9, 2022, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register adding Methiopropamine to schedule I of the federal Controlled Substances Act. The scheduling action is effective January 9, 2023.
2. The Controlled Substances Board did not receive an objection to similarly listing Methiopropamine as a schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing Methiopropamine as a schedule I controlled substance.
3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing Methiopropamine as a schedule I controlled substance.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Methiopropamine under chapter 961, Stats. by creating the following:

Note: Sections CSB 2.01 to 2.99 have been moved to the end of this chapter.

CSB 2.001 Addition of Methiopropamine to Schedule I. Section 961.14 (7) (t), Stats., is created to read:

961.14 (7) (t) N-methyl-1-(thiophen-2-yl)propan-2-amine, commonly known as Methiopropamine.

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated 03/24/23

Douglas Englebert

Doug Englebert, Chair
Controlled Substances Board